Relay Therapeutics, Inc.
RLAY
Kedudukan dalam Saham
#4224
Relay Therapeutics, Inc. is a precision medicine company currently engaged in... Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Harga Saham
$17.16
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$3.76B
Perubahan (1 hari)
5.41%
Perubahan (1 tahun)
140.34%
Negara
US
Perdagangan Relay Therapeutics, Inc. (RLAY)
Kategori
Healthcare
Bilangan saham terbitan bagi Relay Therapeutics, Inc. (RLAY)
Bilangan saham terbitan setakat June 2026: 202.85M
Menurut laporan kewangan terkini dan harga saham Relay Therapeutics, Inc., bilangan saham terbitan semasa ialah 202.85M. Pada akhir December 2023, syarikat mempunyai 122.58M saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk Relay Therapeutics, Inc. (RLAY) dari 2018 hingga 2026
Saham terbitan pada akhir setiap tahun
| Tahun | Saham Terbitan | Ubah |
|---|---|---|
| 2026 (TTM) | 202.85M | 41.98% |
| 2024 | 142.87M | 16.55% |
| 2023 | 122.58M | 9.22% |
| 2022 | 112.23M | 17.97% |
| 2021 | 95.14M | 5.65% |
| 2020 | 90.05M | 2,003.45% |
| 2019 | 4.28M | 72.27% |
| 2018 | 2.49M | 0.00% |
Saham terbitan bagi syarikat atau pesaing yang serupa
| Syarikat | Saham Terbitan | Perbezaan | Negara |
|---|---|---|---|
| 253.90M | 25.17% |
US
|
|
| 396.00M | 95.22% |
US
|
|
| 478.91M | 136.09% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -69.34% |
NL
|
